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Abstract
Background: To identify pretreatment carcinoembryonic antigen (CEA) levels as a risk factor for para-aortic lymph
node (PALN) recurrence following concurrent chemoradiotherapy (CCRT) for cervical cancer.
Methods: From March 1995 to January 2008, 188 patients with squamous cell carcinoma (SCC) of the uterine
cervix were analyzed retrospectively. No patient received PALN irradiation as the initial treatment. CEA and
squamous cell carcinoma antigen (SCC-Ag) were measured before and after radiotherapy. PALN recurrence was
detected by computer tomography (CT) scans. We analyzed the actuarial rates of PALN recurrence by using
Kaplan-Meier curves. Multivariate analyses were carried out with Cox regression models. We stratified the risk
groups based on the hazard ratios (HR).
Results: Both pretreatment CEA levels ≥ 10 ng/mL and SCC-Ag levels < 10 ng/mL (p < 0.001, HR = 8.838), SCC-Ag
levels ≥ 40 ng/mL (p < 0.001, HR = 12.551), and SCC-Ag levels of 10-40 ng/mL (p < 0.001, HR = 4.2464) were
significant factors for PALN recurrence. The corresponding 5-year PALN recurrence rates were 51.5%, 84.8%, and
27.5%, respectively. The 5-year PALN recurrence rate for patients with both low (< 10 ng/mL) SCC and CEA was
only 9.6%. CEA levels ≥ 10 ng/mL or SCC-Ag levels ≥ 10 ng/mL at PALN recurrence were associated with overall
survival after an isolated PALN recurrence. Pretreatment CEA levels ≥ 10 ng/mL were also associated with survival
after an isolated PALN recurrence.
Conclusions: Pretreatment CEA ≥ 10 ng/mL is an additional risk factor of PALN relapse following definitive CCRT
for SCC of the uterine cervix in patients with pretreatment SCC-Ag levels < 10 ng/mL. More comprehensive
examinations before CCRT and intensive follow-up schedules are suggested for early detection and salvage in
patients with SCC-Ag or CEA levels ≥ 10 ng/mL.
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Although concurrent chemoradiotherapy (CCRT) is a
standard treatment for locally advanced cervical cancer
[1,2], para-aortic lymph node (PALN) recurrence was
not uncommon in our prior study, demonstrating that
pelvic CCRT did not decrease PALN recurrence more
than pelvic RT alone [3]. Hence, the strategy to reduce
PALN recurrence is an important issue for the treat-
ment of locally advanced cervical cancer. In addition to
stage, squamous cell carcinoma antigen (SCC-Ag) is an
important tumor marker in the prediction of overall sur-
vival [4], disease-specific survival [4], and distant metas-
tasis [5] in patients undergoing RT alone. We first
identified SCC-Ag as a significant factor of PALN recur-
rence in patients treated with definitive radiotherapy or
CCRT [3]. However, the impact of the other tumor mar-
ker, carcinoembryonic antigen (CEA), in PALN recur-
rence is not clear in patients undergoing pelvic CCRT.
In our clinical practice, CEA may be a potential risk fac-
tor for PALN recurrence in addition to SCC-Ag.
The aim of this retrospective study is to identify CEA
as a risk factor for PALN recurrence following definitive
CCRT for squamous cell carcinoma of the cervix. We
performed risk stratification of PALN recurrence based
on levels of tumor markers, and we recommend com-
prehensive detection of PALN metastasis or intensive
surveillance of patients at risk of PALN recurrence,
especially those patients with both high CEA and low
SCC-Ag levels.
Methods
Patients’ characteristics
Between March 1995 and January 2008, we retrospec-
tively reviewed 246 consecutive patients with histologi-
cally proven squamous cell carcinoma of the cervix
undergoing CCRT. These patients had an Eastern Coop-
erative Oncology Group (ECOG) performance status of
0-2, Federation Internationale de Gynecologie et d’Ob-
stetrique (FIGO) Stage IB-IVA without PALN metastasis
on a CT scan, and an intact uterus. For the purpose of
this study, we excluded 19 patients without a pretreat-
ment CEA/SCC-Ag measurement and 39 patients with-
out an abdominal CT scan examination during follow-
up. Finally, 188 patients were included in this review.
The characteristics of these patients are shown in Table
1. Prior to radiotherapy, patients were evaluated by phy-
sical examination, routine laboratory tests (such as CEA,
SCC-Ag, complete blood count, creatinine, and blood
urea nitrogen), abdominal-pelvic computed tomography
(CT) scan, and chest x-ray. No patient received a PET
scan examination at diagnosis. Scoring for parametrial
(PM) involvement was based on the concept of tumor
burden in previous studies [6,7].
The institutional review board of our Hospital
approved the present study (99-2005B).
External beam radiation therapy (EBRT)
All patients initially received external beam radiation
therapy (EBRT) of the pelvis. Typically, the four-field
technique was used for orthogonal films or a CT-based
simulation. In patients with anteroposterior/posteroan-
terior (AP/PA) or four-field irradiation, the whole-pelvic
(WP) fields were arranged as follows. The upper border
of the AP/PA fields was located at the L4-5 passage.
The lateral border was 1.5-2 cm beyond the widest part
of the pelvic brim. For the bilateral fields, the anterior
Table 1 Patient characteristics (n = 188)
Parameters No. (%) Mean ± SEM
Age (years) 56.5 ± 0.8
Stage
I 22 (11.7%)
II 125 (66.5%)
III 37 (19.7%)
IV 4 (2.1%)
Smoking
No 173 (92.0%)
Yes 15 (8.0%)
Pelvic lymphadenopathy on CT scan
No 167 (88.8%)
Yes 21 (11.2%)
Parametrial scores
0 36 (19.1%)
1-3 103 (54.8%)
4-6 49 (26.1%)
Hemoglobin (g/dL) 11.1 ± 0.2
Field size (Y-axis) (cm) 18.3 ± 0.1
HDR dose to point A (Gy) 24.3 ± 0.2
RT duration (days) 61.2 ± 1.1
Pretreatment SCC-Ag level (ng/mL) 15.2 ± 2.3
< 2 60 (31.9%)
2-10 68 (36.2%)
10-20 21 (11.6%)
20-40 21 (11.6%)
≥ 40 18 (9.6%)
Pretreatment CEA level (ng/mL) 7.7 ± 1.7
< 5 149 (79.3%)
5-10 16 (8.5%)
≥ 10 23 (12.2%)
EBRT technique
AP/PA 2 (1.1%)
Four-field 174 (92.6%)
IMRT 12 (6.4%)
EBRT dose (Gy)
Central dose 42.2 ± 0.3
Parametrial dose 47.2 ± 0.4
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Page 2 of 8border was the anterior part of the pubic symphysis.
The posterior border was at least behind the S2-3 pas-
sage. Modification of the WP fields may depend on the
physician’s decisions about such factors as old age and a
lower small-bowel position. In 12 patients undergoing
IMRT, the clinical target volume (CTV) included the
gross tumor, uterus, parametrium, pelvic side wall,
regional lymph nodes (presacral, common iliac, and
internal iliac and external iliac), and vagina. The plan-
ning target volume (PTV) was expanded 10 mm from
CTV. IMRT was planned (CadPlan, Subiaco, Australia)
and delivered through 5 to 7 fields by 6 MV photons.
The dose per fraction was 1.8 Gy, 5 fractions weekly.
The planning dose was 39.6-45 Gy/22-25 fractions for
the initial pelvic fields. An additional boost (5.4-18 Gy/
3-10 fractions) was given to the bilateral PM or low pel-
vis in patients with cervical cancer advanced beyond
Stage IIA. Monthly concurrent cisplatin chemotherapy
and 5-FU-based concurrent chemotherapy for 1-8
courses (median 3) was used in all patients. The typical
dose of cisplatin was 50 mg/m
2, followed by 5-FU 4 gm
through a 96-hour infusion.
High dose-rate intracavitary brachytherapy (HDR-ICBT)
After completion of EBRT, patients underwent high-
dose-rate intracavitary brachytherapy (HDR-ICBT) that
delivered a boost of radiation to the cervical tumor
through a remote afterloading system (microSelectron,
Nucletron Co., The Netherlands). The isotope was
192Ir
sources. The applicator was the Henschke’s type. Before
applicator implantation, patients received local vaginal
application of lidocaine spray and/or intramuscular
pethidine injections for anesthesia. After dilatation of
the cervical canal, the applicator was inserted into the
uterine cavity and bilateral fornix. The vaginal canal was
p a c k e dw i t hg a u z et os p a r ei tf r o mt h eh i g hd o s eo f
radiation in the bladder and rectum. Orthogonal films
w e r et a k e nf o rd o s ec a l c u l a t i o ni nt h ep l a n n i n gs y s t e m
(TheraPlan 500, Theratronics Co., Canada; Nucletron
PLATO-RTS version 2.0, The Netherlands). The dose
optimization was described in our previous study [8].
The prescribed dose was 3.5-6 Gy at Point A for 4-6
fractions (median 5), and was delivered twice per week;
the exact dose and fractions depended on the physician’s
decision and the patient’s condition.
Tumor markers measurement
Measurement of CEA and SCC-Ag were performed by
radioimmunoassay. After 2005, the method of SCC-Ag
assay was changed to electrochemiluminescence immu-
noassay. The pretreatment measurement was 1-2 weeks
before CCRT. The frequency of tumor markers mea-
surement during CCRT was dependent on physician’s
preference. They were checked usually in the
completion of EBRT and ICBT. Although tumor mar-
kers were routinely checked after complete of CCRT,
the variation of frequency and interval was based on
physician’s preference, interval of follow-up, and disease
status. Once treatment failure such as PALN recurrence,
distant metastasis, or locoregional recurrence was
detected, the tumor markers were checked simulta-
neously for additional information.
Follow-up
After the completion of radiotherapy, follow-ups of
patients were scheduled in the department of Radiation
and/or Gynecological oncology. Laboratory tests, chest
x-ray, physical examination, and CT scan examination
were carried out. A radiologist diagnosed PALN recur-
rence using an abdominal CT scan. Isolated PALN
recurrence was defined as the first site of recurrence
without concurrent locoregional or distant failure. Non-
isolated PALN recurrence was defined as PALN recur-
rence along with other failure(s). For example, PALN
recurrence with coexisting or following distant organ
metastasis or locoregional recurrence. The PALN recur-
rence-free interval was calculated from the completion
of radiotherapy to the last CT scan examination show-
ing no evidence of PALN recurrence with or without
distant organ metastasis.
Statistics
The univariate analysis of PALN recurrence was carried
out by the Kaplan-Meier method, and the statistical sig-
nificance of the different groups was tested by the log-
rank test. We used the Cox proportional hazards model
with the stepwise forward procedure for multivariate
analysis. We input the following variables into a regres-
sion model. All variables such as age, stage, PM score,
tumor size, pelvic lymphadenopathy, radiation field size,
smoking, hemoglobin level, pretreatment CEA, and
SCC-Ag level for Cox regression were considered as
categorical data. A p value < 0.05 was statistically signifi-
cant. The relative risk of PALN recurrence was repre-
sented by the hazard ratio (HR) with a 95% confidence
interval (CI) in the Cox regression. Data processing and
statistics were carried out on a personal computer using
t h eS P S S1 7 . 0s o f t w a r ef o rW i n d o w s( S P S SI n c . ,C h i -
cago, USA).
Results
Outcome of PALN recurrence
The median time of follow-up was 58.2 months (range
3.6-178.2). Following radiotherapy, 35 patients (18.6%)
had PALN recurrence. There were 19 patients (8.6%)
with isolated PALN recurrence. PALN recurrence was
detected by routine CT scan examination in 7 patients
(20%) without increased tumor markers or symptoms.
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isolated PALN recurrence were 16.7 ± 4.2 and 45.4 ±
16.7 ng/mL, respectively. The corresponding CEA levels
were 5.2 ± 1.3 and 25.1 ± 14.8 ng/mL.
The 5-year actuarial PALN recurrence rates were
23.8%. No further treatment was noted in 13 patients.
At the time, 12, 1, and 9 patients were undergoing
radiotherapy plus chemotherapy, radiotherapy, and che-
motherapy for salvage, respectively. The 3-year overall
survival rates after non- isolated PALN recurrence were
7%. The corresponding rates of isolated PALN recur-
rence were 40.9%. The 3-year survival rates in patients
with isolated recurrence were 52.7% and 0% (p <0 . 0 0 1 )
at SCC-Ag levels < 10 and ≥ 10 ng/mL of isolated
PALN recurrence (Figure 1A), respectively. However,
pretreatment SCC-Ag levels did not affect survival rates
after isolated PALN recurrence (p = 0.146) (Figure 1B).
Both CEA levels ≥ 10 ng/mL (p = 0.039) at PALN
recurrence (Figure 2A) and pretreatment CEA levels ≥
10 ng/mL (p = 0.038) (Figure 2B) were prognostic fac-
tors of overall survival following isolated PALN recur-
rence. The 3-year survival rate was 64.8% in patients
undergoing salvage CCRT for isolated PALN recurrence.
Multivariate analyses of PALN recurrence
We performed multivariate analysis for factors predic-
tive of PALN recurrence (Table 2). CEA levels ≥ 10 ng/
mL (p = 0.001), SCC-Ag levels 10-40 ng/mL (p = 0.018),
SCC-Ag levels ≥ 40 ng/mL (p < 0.001) were significant
factors in the first Cox regression. Based on our prior
study [9], CEA can interact with SCC-Ag levels for
prognosis. We performed a second Cox regression con-
sidering the interaction between CEA levels and SCC-
Ag levels and noted the interaction (p < 0.001). Hence,
we categorized the new tumor marker groups as CEA
levels < 10 ng/mL and ≥ 10 ng/mL in patients with SCC
levels < 10 ng/mL. The remaining groups of SCC-Ag
levels were 10-40 ng/mL and ≥ 40 ng/mL. We per-
formed the third Cox regression (Table 3) and noted
that both CEA ≥ 10 ng/mL and SCC-Ag levels < 10 ng/
mL (p < 0.001) and SCC-Ag levels ≥ 40 ng/mL (p <
0.001), and SCC-Ag levels of 10-40 ng/mL (p=0.002)
were significant factors.
PALN recurrence rates in relation to tumor marker
combinations
Patients with SCC-Ag levels ≥ 40 ng/mL, both CEA ≥
10 ng/mL and SCC-Ag levels < 10 ng/mL, SCC-Ag
levels of 10-40 ng/mL, and SCC-Ag levels of < 10 ng/
mL had a 5-year PALN recurrence rate of 84.8%, 51.5%,
27.5%, and 9.6% (p < 0.001) (Figure 3), respectively.
Hence, we categorized patients with SCC-Ag levels ≥ 40
ng/mL or both CEA ≥ 10 ng/mL and SCC-Ag levels <
10 ng/mL as the high-risk group (n = 33), in which the
5-year PALN recurrence rate was 66.5%. Patients with
SCC-Ag levels of 10-40 ng/mL and SCC-Ag levels of <
10 ng/mL made up the intermediate- (n = 42) and low-
risk group (n = 113), respectively.
Discussion
CCRT improves the treatment outcome of locally
advanced cervical cancer [1,2]. Morris et al. conducted a
randomized trial to compare whole pelvic CCRT with
extended field radiotherapy (EFRT) alone [1]. They
found that CCRT improved overall survival and disease-
free survival, as well as decreased locoregional and dis-
tant failure to a greater extent than EFRT. However, the
5-year recurrence rate of para-aortic lymph node
(PALN) was 7% and 4% (p =0 . 1 5 )i nt h ep e l v i cC C R T
and EFRT groups in the updated data of the same study
[10], respectively. Eifel et al. thought that the decrease
of distant failure was attributable to a decrease of sec-
ondary spread from uncontrolled pelvic disease [10]. In
our prior study, pelvic CCRT did not decrease PALN
recurrence to a greater extent than pelvic RT alone [3].
Hence, cisplatin and 5-FU plus pelvic RT may not
directly eradicate PALN recurrence. To eliminate PALN
micrometastasis and recurrence, more aggressive
Figure 1 (A) SCC-Ag ≥ 10 ng/mL at recurrence but not (B) pretreatment SCC-Ag levels predicted overall survival after isolated PALN
recurrence.
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phylactic PALN irradiation, or additional chemotherapy
should be considered in future clinical trials. Risk strati-
fication is helpful to establish the eligibility of patients
for the clinical trial.
PALN recurrence after definitive radiotherapy with or
without concurrent chemotherapy is not uncommon in
clinical practice. Niibe et al. proposed the concept of oli-
gorecurrence and compared with oligometastasis [11].
PALN recurrence may be presented as either oligorecur-
rence or oligometastasis. Isolated PALN recurrence is
Figure 2 (A) CEA ≥ 10 ng/mL at recurrence and (B) pretreatment CEA levels predicted overall survival after isolated PALN recurrence.
Table 2 Multivariate analysis of PALN recurrence
Parameters Number Hazard ratio (95%
CI)
p
value
Age 0.233
< 50 58 reference
50-60 59 – 0.124
>6 0 7 1 – 0.141
Stage 0.831
I 22 reference
II 145 – 0.852
III-IVA 41 – 0.686
Parametrial score 0.056
0 36 reference
1-3 103 – 0.749
4-6 49 – 0.222
Tumor size (cm) 0.333
≤ 5.0 48 reference
> 5.0 53 0.304
unknown 87 0.836
Positive pelvic node – 0.170
Hemoglobin < 12 g/dL – 0.525
Smoking – 0.484
Field size (< 18 cm) – 0.959
Pretreatment CEA level (ng/
mL)
0.005
< 5 149 reference
5-10 16 1.007 (0.232-4.365) 0.993
≥ 10 23 4.206 (1.801-9.821) 0.001
Pretreatment SCC-Ag level
(ng/mL)
<
0.001
< 10 128 reference
10-40 42 2.617 (1.180-5.804) 0.018
≥ 40 18 6.851 (2.722-16.935) <
0.001
Abbreviations: CI = confidence interval; SCC-Ag = squamous cell carcinoma
antigen; CEA = Carcinoembryonic antigen
Table 3 Multivariate analysis of PALN recurrence using
CEA levels integrated into SCC-Ag level < 10 ng/mL
Parameters Number Hazard ratio (95%
CI)
p
value
Age – 0.323
< 50 58 reference
50-60 59 – 0.155
>6 0 7 1 – 0.233
Stage – 0.609
I 22 reference
II 145 – 0.629
III-IVA 41 – 0.372
Parametrial score – 0.121
0 36 reference
1-3 103 – 0.111
4-6 49 – 0.040
Tumor size 0.651
≤ 5.0 48 reference
> 5.0 53 – 0.517
unknown 87 – 0.864
Positive pelvic node – 0.075
Hemoglobin < 12 g/dL – 0.303
Smoking – 0.528
Field size (< 18 cm) – 0.874
Pretreatment tumor marker
(ng/mL)
<
0.001
SCC-Ag < 10 and CEA <
10
113 reference
SCC-Ag < 10 and CEA ≥
10
15 8.838 (3.199-24.419) <
0.001
SCC-Ag 10-40 42 4.246 (1.706-10.569) 0.002
SCC-Ag ≥ 40 18 12.551 (4.811-
32.747)
<
0.001
Abbreviations: CI = confidence interval; SCC-Ag = squamous cell carcinoma
antigen; CEA = Carcinoembryonic antigen
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large population study (n = 3137) demonstrated that the
incidence of isolated PALN recurrence was 2.1% [12].
The mean pretreatment SCC-Ag level was 17.3 ng/mL
[12] that is similar to 16.7 ng/mL of present study. The
correlation (r = 0.653; p = 0.002) between pretreatment
and recurrence SCC-Ag level also confirmed the study
of Niibe et al. [12]. The 5-year survival is around 30%
for this type of oligorecurrence in our systematic review
[3]. Non-isolated PALN recurrence often presents as oli-
gometastasis that primary tumor is not controlled or
with concurrent distant metastasis. The outcome is poor
from our prior [3] and present results.
Whereas Eifel et al. reported a 5-year PALN recur-
rence of 7% following pelvic CCRT, our previous report
[3] revealed a 5-year actuarial rate of 14%. In the pre-
sent study, focusing on patients undergoing CCRT, the
corresponding rate was 23.8%. Yeung et al. reported a
PALN relapse rate of 15.3% in Stage IIIB/IVA patients
[13]. Variations of PALN recurrence rates may depend
on many factors related to physicians and patients. An
intensive follow-up schedule could detect a higher rate
of PALN recurrence [14]. Because the diagnosis is based
on CT, MRI, or PET, unlike chest x-ray, these examina-
tions are more expensive and cost-effectiveness is ques-
tionable. Many physicians do not perform intensive CT,
MRI, or PET examinations at follow-up if normal tumor
markers or no recurrent symptoms/signs are noted. The
diagnosis of PALN recurrence may be delayed if tumor
markers are not evaluated during routine follow-up.
Once a patient shows clinically relevant failures, such as
local failure, lung metastasis, or supraclavicular LN
metastasis, the examination of PALN metastasis may be
omitted and replaced with palliative care. Hence, the
real incidence of PALN recurrence may be greater than
the present data reflects. The distribution of poor
prognostic factors in patients may be related to the inci-
dence of PALN recurrence. The aim of the current
study was to identify the risk factors.
We first identified CEA levels ≥ 10 ng/mL in patients
with SCC-Ag levels < 10 ng/mL as a high-risk factor.
Traditionally, SCC-Ag levels < 10 ng/mL is thought to
be a low-risk factor [4]. The percentage of CEA levels ≥
10 ng/mL was as small as 9.9% in patients with SCC-Ag
levels < 10 ng/mL. This subgroup is easily overlooked
because no study has demonstrated the role of CEA in
PALN recurrence for squamous cell carcinoma of cervix.
The onset of PALN recurrence was rapid and 2-year
actuarial rate was high as 50%. Hence, CEA levels may
be considered as an indicator of occult PALN metastasis
in this subgroup. In addition, SCC-Ag levels ≥ 40 ng/
mL was the other major risk factor of PALN recurrence.
Based on HR and PALN recurrent rates, patients with
SCC-Ag levels ≥ 40 ng/mL and CEA levels ≥ 10 ng/mL/
SCC-Ag levels < 10 ng/mL were assigned to the high-
risk group. Patients with SCC-Ag levels between 10 and
40 ng/mL made up the intermediate-risk group. Patients
with both SCC-Ag and CEA levels < 10 ng/mL made up
the low-risk group. We strongly suggest para-aortic lym-
phadenoectomy or PET-CT examination for planning
the treatment of radiotherapy in intermediate- to high-
risk patients. If isolated PALN metastasis is detected at
the initial diagnosis of cervical cancer, the RT field
should be extended to PALN lesions. Furthermore,
PET-CT examination is suggested for patients with iso-
lated PALN recurrence diagnosed with a CT scan to
exclude another distant metastasis.
Some patients with occult PALN micrometastasis are
at risk for PALN recurrence if they undergo pelvic
CCRT for CT-negative PALN metastasis. Hence, para-
aortic lymphadenoectomy can confirm subclinical PALN
micrometastasis. Minimal complications are acceptable
in modern laparoscopic technique providing that CCRT
is not delayed [15,16]. A large series study (n = 253)
[17] reports that for 17.9% of patients with pathology-
confirmed PALN metastasis, their metastases were not
detected in the CT scan at initial diagnosis of cervical
cancer. The false negative rate of CT detection [18] was
23% in patients with laparoscopic extraperitoneal para-
aortic lymphadenectomy. Taken together, the false nega-
tive CT detection rates of around 20% are compatible
with the current incidence of PALN recurrence (18.6%).
This finding implies that PALN recurrence may result
from suboptimal pelvic CCRT for PALN micrometasta-
sis. There are some advantages of laparoscopic extraper-
itoneal para-aortic lymphadenectomy. For example, it
can prevent intermediate- to high-risk patients from
receiving suboptimal treatment for pelvic radiotherapy.
In addition, some intermediate- to high-risk patients
with true-negative PALN metastasis are exempt from
Figure 3 PALN recurrent rates for various combinations of
pretreatment of CEA and SCC-Ag levels.
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and renal toxicity are the major concerns. Hence, we
suggest that screening for PALN metastasis in high-risk
patients should be a priority. If laparoscopic extraperito-
neal para-aortic lymphadenoectomy cannot be per-
formed before radiotherapy for certain reasons, the
PET-CT scan can be used as the alternative approach to
detect PALN metastasis because of its false negative rate
of 8.4% [16]. Prophylactic PALN irradiation is preserved
in high-risk patients without para-aortic lymphadenoect-
omy or PET-CT scan examination. IMRT is suggested
for prophylactic PALN plus CCRT because of acceptable
acute, early, and late toxicities [19].
The prognostic factors of isolated PALN recurrence
were CEA and SCC-Ag levels ≥ 10 ng/mL at recurrence
and CEA levels ≥ 10 ng/mL at initial diagnosis.
Although small number of isolated PALN recurrence,
marginally statistical significance, and no long-term fol-
low-up were noted, it is reasonable for impact of high
markers at isolated PALN recurrence on survival
because high SCC-Ag/CEA levels may be related to
occult distant organ metastasis. Hence, early detection
of PALN recurrence is very important for outcome
because early isolated PALN recurrence can be salvaged
[20] and tumor marker levels at PALN recurrence affect
survival rate [3,21]. Because 40% of patients belonged to
the intermediate to high-risk groups in our analysis, we
suggest that intensive follow-up planning, such as SCC-
A g ,C E A ,a n dC Ts c a n ,i ni n t ermediate- to high-risk
patients is indispensable to the early detection of PALN
recurrence and early salvage. The current analysis
demonstrated that no elevation of tumor markers and
no symptoms were noted in 20% of PALN recurrences.
Hence, tumor marker testing is not the only way to
screen for PALN recurrence. Routine CT scan examina-
tion should be scheduled at follow-up.
Interestingly, initial CEA but not SCC-Ag levels could
predict overall survival following isolated PALN recur-
rence. CEA is involved in brain metastasis of lung can-
cer [22] and liver metastasis of gastric cancer [23].
Moreno García et al. noted that the pretreatment CEA
level was a prognostic factor of DFS, complete patholo-
gic responses, and recurrences [24]. In Dukes’ C2 rectal
cancer, hepatic and local recurrence rates were higher in
the patients with > 10 ng/mL of CEA than were those in
the patients with < or = 5 ng/mL of CEA [25]. Hostetter
et al. used a recombined CEA injection in mice and
noted CEA-enhanced liver metastasis of colon cancer
cells [26]. Hence, CEA may be a marker of PALN
micrometastasis before CCRT for cervical cancer.
This study has strengths and some limitations. This is
the first study to investigate the role of CEA and SCC-
Ag levels in PALN recurrence following pelvic CCRT.
We identify 3 risk groups and suggest intensive survey
in intermediate- to high-risk patients. Patients with both
CEA ≥ 10 ng/mL and SCC-Ag levels < 10 ng/mL should
be managed with caution because they are at high risk
for PALN recurrence. Compared with our prior study
[3], this study is specific to patients undergoing CCRT
and identifies CEA as a significant risk factor. We did
not perform biopsy for tissue proof of isolated PALN
recurrence, and only 4 patients had PET-CT examina-
tion, which was limited by the health insurance in our
country. However, the outcome of isolated PALN recur-
rence was compatible with other studies [5,20,27]. In
227 patients, we excluded 39 patients without CT scan
follow-up. Hence, the PALN recurrent rate may be over-
estimated because these 36 patients had low SCC-Ag
levels (data not shown).
In conclusion, in addition to SCC-Ag levels, CEA is
another important risk factor for PALN recurrence,
especially in patients with SCC-Ag levels < 10 ng/mL.
In those patients or patients with SCC-Ag levels ≥ 10
ng/mL, laparoscopic extraperitoneal para-aortic lympha-
denectomy, PET-CT examination, or prophylactic PALN
irradiation for radiotherapy planning should be consid-
ered first. Comprehensive evaluations before and after
radiotherapy should be carried out. We suggest that
clinical trials for aggressive detection and management
of PALN metastasis are needed for the improvement of
treatment outcome in these patients.
Acknowledgements
Presented in the 52nd Annual Meeting of American Society for Therapeutic
Radiology and Oncology (ASTRO), Oct. 31-Nov. 4, 2010, San Diego, USA.
Author details
1Department of Radiation Oncology, Kaohsiung Chang Gung Memorial
Hospital, Chang Gung University College of Medicine, Kaohsiung, Taiwan.
2Department of Gynecologic Oncology, Kaohsiung Chang Gung Memorial
Hospital, Chang Gung University College of Medicine, Kaohsiung, Taiwan.
3School of Traditional Chinese Medicine, Chang Gung University College of
Medicine, Taoyuan, Taiwan.
4School of Medicine, Chang Gung University
College of Medicine, Taoyuan, Taiwan.
5Department of Radiation Oncology,
Zuoying Armed Forces General Hospital, Kaohsiung, Taiwan.
6Department of
Gynecologic Oncology, Chia-Yi Chang Gung Memorial Hospital, Chia-Yi,
Taiwan.
Authors’ contributions
EYH and YJH participated in design and coordination of study. EYH, YJ H,
CCC, HL, CJW, LMS, CWT, CCT, YCO, HCF, HCC, HCH, and CYW participated in
data acquisition. EYH and YJH contributed to the statistical analysis. EYH,
YJH, CCW, CCC, and HL contributed to interpretation of data. EYH and YJH
drafted the article and all other authors helped and finally approved the
final manuscript.
Competing interests
The authors declare that they have no competing interests.
Received: 23 July 2011 Accepted: 30 January 2012
Published: 30 January 2012
References
1. Morris M, Eifel PJ, Lu J, Grigsby PW, Levenback C, Stevens RE, Rotman M,
Gershenson DM, Mutch DG: Pelvic radiation with concurrent
Huang et al. Radiation Oncology 2012, 7:13
http://www.ro-journal.com/content/7/1/13
Page 7 of 8chemotherapy compared with pelvic and para-aortic radiation for high-
risk cervical cancer. New Engl J Med 1999, 340(15):1137-1143.
2. Rose PG, Bundy BN, Watkins EB, Thigpen JT, Deppe G, Maiman MA, Clarke-
Pearson DL, Insalaco S: Concurrent cisplatin-based radiotherapy and
chemotherapy for locally advanced cervical cancer. N Engl J Med 1999,
340(15):1144-1153.
3. Huang EY, Wang CJ, Chen HC, Fang FM, Huang YJ, Wang CY, Hsu H:
Multivariate analysis of para-aortic lymph node recurrence after
definitive radiotherapy for stage IB-IVA squamous cell carcinoma of
uterine cervix. Int J Radiat Oncol Biol Phys 2008, 72(3):834-842.
4. Hong JH, Tsai CS, Chang JT, Wang CC, Lai CH, Lee SP, Tseng CJ, Chang TC,
Tang SG: The prognostic significance of pre- and posttreatment SCC
levels in patients with squamous cell carcinoma of the cervix treated by
radiotherapy. Int J Radiat Oncol Biol Phys 1998, 41(4):823-830.
5. Hong JH, Tsai CS, Lai CH, Chang TC, Wang CC, Chou HH, Lee SP, Hsueh S:
Recurrent squamous cell carcinoma of cervix after definitive
radiotherapy. Int J Radiat Oncol Biol Phys 2004, 60(1):249-257.
6. Arthur D, Kaufman N, Schmidt-Ullrich R, Kavanagh B, Simpson P, Hill M,
Ali M: Heuristically derived tumor burden score as a prognostic factor
for stage IIIB carcinoma of the cervix. Int J Radiat Oncol Biol Phys 1995,
31(4):743-751.
7. Hsu HC, Leung SW, Huang EY, Wang CJ, Sun LM, Fang FM, Chen HC:
Impact of the extent of parametrial involvement in patients with
carcinoma of the uterine cervix. Int J Radiat Oncol Biol Phys 1998,
40(2):405-410.
8. Huang EY, Wang CJ, Lan JH, Chen HC, Fang FM, Hsu HC, Huang YJ,
Wang CY, Wang YM: Factors for predicting rectal dose of high-dose-rate
intracavitary brachytherapy after pelvic irradiation in patients with
cervical cancer: a retrospective study with radiography-based dosimetry.
Int J Radiat Oncol Biol Phys 2010, 76(2):490-495.
9. Huang EY, Hsu HC, Sun LM, Chanchien CC, Lin H, Chen HC, Tseng CW,
Ou YC, Chang HY, Fang FM, Huang YJ, Wang CY, Lu HM, Tsai CC, Ma YY,
Fu HC, Wang YM, Wang CJ: Prognostic value of pretreatment
carcinoembryonic antigen after definitive radiotherapy with or without
concurrent chemotherapy for squamous cell carcinoma of the uterine
cervix. Int J Radiat Oncol Biol Phys 2011, 81(4):1105-1113.
10. Eifel PJ, Winter K, Morris M, Levenback C, Grigsby PW, Cooper J, Rotman M,
Gershenson D, Mutch DG: Pelvic irradiation with concurrent
chemotherapy versus pelvic and para-aortic irradiation for high-risk
cervical cancer: an update of radiation therapy oncology group trial
(RTOG) 90-01. J Clin Oncol 2004, 22(5):872-880.
11. Niibe Y, Hayakawa K: Oligometastases and oligo-recurrence: the new era
of cancer therapy. Jpn J Clin Oncol 2010, 40(2):107-111.
12. Niibe Y, Kazumoto T, Toita T, Yamazaki H, Higuchi K, Ii N, Suzuki K, Uno T,
Tokumaru S, Takayama M, Sekiguchi K, Matsumoto Y, Michimoto K,
Oguchi M, Hayakawa K: Frequency and characteristics of isolated para-
aortic lymph node recurrence in patients with uterine cervical
carcinoma in Japan: a multi-institutional study. Gynecol Oncol 2006,
103(2):435-438.
13. Yeung AR, Amdur RJ, Morris CG, Morgan LS, Mendenhall WM: Long-term
outcome after radiotherapy for FIGO stage IIIB and IVA carcinoma of the
cervix. Int J Radiat Oncol Biol Phys 2007, 67(5):1445-1450.
14. Sakurai H, Mitsuhashi N, Takahashi M, Akimoto T, Muramatsu H, Ishikawa H,
Imai R, Yamakawa M, Hasegawa M, Niibe H: Analysis of recurrence of
squamous cell carcinoma of the uterine cervix after definitive radiation
therapy alone: patterns of recurrence, latent periods, and prognosis. Int J
Radiat Oncol Biol Phys 2001, 50(5):1136-1144.
15. Leblanc E, Gauthier H, Querleu D, Ferron G, Zerdoud S, Morice P, Uzan C,
Lumbroso S, Lecuru F, Bats AS, Ghazzar N, Bannier M, Houvenaeghel G,
Brenot-Rossi I, Narducci F: Accuracy of 18-fluoro-2-deoxy-D-glucose
positron emission tomography in the pretherapeutic detection of occult
para-aortic node involvement in patients with a locally advanced
cervical carcinoma. Ann Surg Oncol 2011, 18(8):2302-2309.
16. Uzan C, Souadka A, Gouy S, Debaere T, Duclos J, Lumbroso J, Haie-
Meder C, Morice P: Analysis of morbidity and clinical implications of
laparoscopic para-aortic lymphadenectomy in a continuous series of 98
patients with advanced-stage cervical cancer and negative PET-CT
imaging in the para-aortic area. Oncologist 2011, 16(7):1021-1027.
17. Heller PB, Maletano JH, Bundy BN, Barnhill DR, Okagaki T: Clinical-
pathologic study of stage IIB, III, and IVA carcinoma of the cervix:
extended diagnostic evaluation for paraaortic node metastasis–a
Gynecologic Oncology Group study. Gynecol Oncol 1990, 38(3):425-430.
18. Ramirez PT, Jhingran A, Macapinlac HA, Euscher ED, Munsell MF,
Coleman RL, Soliman PT, Schmeler KM, Frumovitz M, Ramondetta LM:
Laparoscopic extraperitoneal para-aortic lymphadenectomy in locally
advanced cervical cancer: a prospective correlation of surgical findings
with positron emission tomography/computed tomography findings.
Cancer 2011, 117(9):1928-1934.
19. Beriwal S, Gan GN, Heron DE, Selvaraj RN, Kim H, Lalonde R, Kelley JL,
Edwards RP: Early clinical outcome with concurrent chemotherapy and
extended-field, intensity-modulated radiotherapy for cervical cancer. Int
J Radiat Oncol Biol Phys 2007, 68(1):166-171.
20. Singh AK, Grigsby PW, Rader JS, Mutch DG, Powell MA: Cervix carcinoma,
concurrent chemoradiotherapy, and salvage of isolated paraaortic
lymph node recurrence. Int J Radiat Oncol Biol Phys 2005, 61(2):450-455.
21. Chou HH, Wang CC, Lai CH, Hong JH, Ng KK, Chang TC, Tseng CJ, Tsai CS,
Chang JT: Isolated paraaortic lymph node recurrence after definitive
irradiation for cervical carcinoma. Int J Radiat Oncol Biol Phys 2001,
51(2):442-488.
22. Arrieta O, Saavedra-Perez D, Kuri R, Aviles-Salas A, Martinez L, Mendoza-
Posada D, Castillo P, Astorga A, Guzman E, De la Garza J: Brain metastasis
development and poor survival associated with carcinoembryonic
antigen (CEA) level in advanced non-small cell lung cancer: a
prospective analysis. BMC Cancer 2009, 9:119.
23. Ikeda Y, Mori M, Kajiyama K, Kamakura T, Maehara Y, Haraguchi Y,
Sugimachi K: Indicative value of carcinoembryonic antigen (CEA) for liver
recurrence following curative resection of stage II and III gastric cancer.
Hepatogastroenterology 1996, 43(11):1281-1287.
24. Moreno García V, Cejas P, Blanco Codesido M, Feliu Batlle J, de Castro
Carpeño J, Belda-Iniesta C, Barriuso J, Sánchez JJ, Larrauri J, González-
Barón M, Casado E: Prognostic value of carcinoembryonic antigen level
in rectal cancer treated with neoadjuvant chemoradiotherapy. Int J
Colorectal Dis 2009, 24(7):741-748.
25. Park JY, Lee KH: Carcinoembryonic antigen and patterns of recurrence
after curative resection of the colorectal cancer. Hepatogastroenterology
2007, 54(79):1966-1969.
26. Hostetter RB, Augustus LB, Mankarious R, Chi KF, Fan D, Toth C, Thomas P,
Jessup JM: Carcinoembryonic antigen as a selective enhancer of
colorectal cancer metastasis. J Natl Cancer Inst 1990, 82(5):380-385.
27. Niibe Y, Kenjo M, Kazumoto T, Michimoto K, Takayama M, Yamauchi C,
Kataoka M, Suzuki K, Ii N, Uno T, Takanaka T, Higuchi K, Yamazaki H,
Tokumaru S, Oguchi M, Hayakawa K, Japanease Isolated Para-Aortic Lymph
Node Recurrence of Uterine Cervical Carcinoma Study Group: Multi-
institutional study of radiation therapy for isolated para-aortic lymph
node recurrence in uterine cervical carcinoma: 84 subjects of a
population of more than 5,000. Int J Radiat Oncol Biol Phys 2006,
66(5):1366-1369.
doi:10.1186/1748-717X-7-13
Cite this article as: Huang et al.: Pretreatment carcinoembryonic antigen
level is a risk factor for para-aortic lymph node recurrence in addition
to squamous cell carcinoma antigen following definitive concurrent
chemoradiotherapy for squamous cell carcinoma of the uterine cervix.
Radiation Oncology 2012 7:13.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Huang et al. Radiation Oncology 2012, 7:13
http://www.ro-journal.com/content/7/1/13
Page 8 of 8